Cover Story
At first glance, it's hard to imagine anything as obscure as a policy by a private contracting firm that runs the Medicare program in the Carolinas, Virginia and West Virginia.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt